Objectives of Study:
|
This study will clarify the clinical effect of acupuncture loosening "Heyangnei" in the treatment of K-LIII-IV KOA to improve the range of joint motion. Using far-infrared thermal imaging instrument, digital tenderness instrument, wireless surface electromyography instrument and muscle tone instrument and other equipment, comprehensively analyze and explore the influence of lower extremity skin temperature and tenderness point changes on the changes of myoelectric signals and soft tissue tension in the periknee muscle group after acupuncture treatment, and reveal the related mechanism of "Tongyang Softening Ribs" improving KOA joint function, and provide a scientific basis for acupuncture "Tongyang Softening Tendon" in the treatment of KOA.
|
Inclusion criteria
|
① Meet the diagnostic standards of Western medicine;
② Imaging conforms to Kellgren-Lawrence grades III-IV;
③ It belongs to medial compartment knee osteoarthritis, pain in the medial knee, narrowing of the medial compartment, and the imaging manifestations of the affected knee joint meet the standards of knee varus (tibiofemoral angle > 175 °);
④ VAS ≥ 4 points;
⑤ BMI < 30;
⑥ Those aged 40-70;
⑦ The subjects have no experience in knee acupuncture treatment and can receive acupuncture treatment;
⑧ Subjects who signed an informed consent form, voluntarily participated in this study, had good compliance, and did not withdraw midway.
|
Exclusion criteria:
|
① Osteoarthritis caused by rheumatoid arthritis, rheumatoid arthritis, gouty arthritis, psoriatic arthritis, hemophiliac arthritis, ankylosing spondylitis, osteomyelitis, bone tumor and bone tuberculosis, as well as lateral compartment type, patellar type, total articular knee osteoarthritis;
② Other diseases that may affect knee osteoarthritis, such as psoriasis, acute trauma, syphilis, diabetes, etc.;
③ Lower extremity pain or dysfunction caused by non-knee diseases;
④ Subjects who are not suitable for acupuncture, such as skin damage, ulceration, local infection, history or clinical manifestations of bleeding tendency (including those currently using anticoagulants);
⑤ Pregnant or breastfeeding subjects;
⑥ Mental, intellectual disabilities, etc., subjects who are difficult to cooperate with treatment;
⑦ Those with impaired heart, liver, kidney and respiratory functions or other serious diseases of various systems;
⑧ Those who are allergic to isopropanol, propylene glycol or other non-steroidal anti-inflammatory drugs.
⑨ Observers who have received other related treatments that may affect the effect indicators of this study;
|